This trial is testing whether adding hyperthermic intraperitoneal chemotherapy to primary cytoreductive surgery improves outcomes for stage III epithelial ovarian cancer.
1 Primary · 3 Secondary · Reporting Duration: 30 days after end of treatment
Active Control
Experimental Treatment
538 Total Participants · 2 Treatment Groups
Primary Treatment: cisplatin · No Placebo Group · Phase 3
Age 18+ · Female Participants · 2 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: